# US 2020/0347118 A1 · Method to improve virus filtration capacity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347118 A1
- Document ID: US20200347118A1
- Status: Published application
- Kind: A1
- Application number: 16/848,564
- Filed: 2020-04-14
- Published: 2020-11-05
- Earliest claimed: 2009-08-06
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Amit MEHTA
- Web page: https://patentgrep.com/patent/US20200347118A1

## CPC

- C07K 16/065: {Purification, fragmentation}
- C07K 1/18: Ion-exchange chromatography
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C07K 1/36: by a combination of two or more processes of different types
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.

## Claims

### Claim 1

A method of improving the filtration capacity of a virus filter during protein purification, comprising subjecting a composition comprising a protein to be purified to a cation exchange step and an endotoxin removal step, simultaneously or in either order, prior to passing through said virus filter.

### Claim 2 (depends on 1)

The method of claim 1 wherein the pore size of the virus filter is between about 15 and about 100 nm diameter.

### Claim 3 (depends on 2)

The method of claim 2 wherein the pore size of the virus filter is between about 15 and about 30 nm diameter.

### Claim 4 (depends on 3)

The method of claim 3 wherein the pore size of the virus filter is about 20 nm.

### Claim 5 (depends on 3)

The method of claim 3 wherein the virus to be removed is a parvovirus.

### Claim 6 (depends on 5)

The method of claim 5 wherein the diameter of the parvovirus is between about 18 and about 26 nm.

### Claim 7 (depends on 1)

The method of claim 1 wherein the protein is an antibody or an antibody fragment.

### Claim 8 (depends on 7)

The method of claim 7 wherein the protein is a recombinant antibody or antibody fragment.

### Claim 9 (depends on 8)

The method of claim 8 wherein the recombinant antibody or antibody fragment is produced in a mammalian host cell.

### Claim 10 (depends on 9)

The method of claim 9 wherein the mammalian host cell is a Chinese Hamster Ovary (CHO) cell.

### Claim 11 (depends on 1)

The method of claim 1 wherein the composition comprising the protein to be purified is first subjected to the cation exchange step followed by the endotoxin removal step, prior to virus filtration.

### Claim 12 (depends on 1)

The method of claim 1 wherein the composition comprising the protein to be purified is first subjected to the endotoxin removal step followed by the cation exchange step, prior to virus filtration.

### Claim 13 (depends on 1)

The method of claim 1 wherein the composition comprising the protein to be purified is subjected to the endotoxin removal step and the cation exchange step simultaneously, prior to virus filtration.

### Claim 14 (depends on 11)

The method of claim 11 wherein said endotoxin removal step is directly followed by virus filtration.

### Claim 15 (depends on 12)

The method of claim 12 wherein said cation exchange step is directly followed by virus filtration.

### Claim 16 (depends on 13)

The method of claim 13 wherein said simultaneous endotoxin removal and cation exchange step are directly followed by virus filtration.

### Claim 17 (depends on 1)

The method of claim 1 wherein virus filtration is performed at a pH between about 4 and about 10.

### Claim 18 (depends on 1)

The method of claim 1 wherein the protein concentration in said composition is about 1-40 g/L.

### Claim 19 (depends on 8)

The method claim 8 wherein said antibody is to one or more antigens selected from the group consisting of HER1 (EGFR), HER2, HER3, HER4, VEGF, CD20, CD22, CD11a, CD11b, CD11c, CD18, an ICAM, VLA-4, VCAM, IL-17A and/or F, IgE, DR5, CD40, Apo2L/TRAIL, EGFL7, NRP1, mitogen activated protein kinase (MAPK), and Factor D.

### Claim 20 (depends on 8)

The method of claim 8 wherein the antibody is selected from the group consisting of anti-estrogen receptor antibody, anti-progesterone receptor antibody, anti-p53 antibody, anti-cathepsin D antibody, anti-Bcl-2 antibody, anti-E-cadherin antibody, anti-CA125 antibody, anti-CA15-3 antibody, anti-CA19-9 antibody, anti-c-erbB-2 antibody, anti-P-glycoprotein antibody, anti-CEA antibody, anti-retinoblastoma protein antibody, anti-ras oncoprotein antibody, anti-Lewis X antibody, anti-Ki-67 antibody, anti-PCNA antibody, anti-CD3 antibody, anti-CD4 antibody, anti-CD5 antibody, anti-CD7 antibody, anti-CD8 antibody, anti-CD9/p24 antibody, anti-CD10 antibody, anti-CD11c antibody, anti-CD13 antibody, anti-CD14 antibody, anti-CD15 antibody, anti-CD19 antibody, anti-CD23 antibody, anti-CD30 antibody, anti-CD31 antibody, anti-CD33 antibody, anti-CD34 antibody, anti-CD35 antibody, anti-CD38 antibody, anti-CD41 antibody, anti-LCA/CD45 antibody, anti-CD45RO antibody, anti-CD45RA antibody, anti-CD39 antibody, anti-CD100 antibody, anti-CD95/Fas antibody, anti-CD99 antibody, anti-CD106 antibody, anti-ubiquitin antibody, anti-CD71 antibody, anti-c-myc antibody, anti-cytokeratins antibody, anti-vimentins antibody, anti-HPV proteins antibody, anti-kappa light chains antibody, anti-lambda light chains antibody, anti-melanosomes antibody, anti-prostate specific antigen antibody, anti-S-100 antibody, anti-tau antigen antibody, anti-fibrin antibody, anti-keratins antibody and anti-Tn-antigen antibody.
